Clinical Trials in San Francisco

Showing 9601-9620 of 12,991 trials

Citalopram in Irritable Bowel Syndrome

NCT00477165

Hypotheses: 1. Primary null hypothesis: The rate of clinical response, assessed as patient-reported global symptom rating and "adequate relief of IBS symptoms," does not differ between non-depressed IBS patients treated with the SSRI citalopram and patients treated with placebo. 2. Secondary null hypotheses: 1. Changes in disease-related quality of life, assessed with the IBS-QOL instrument, do not differ between patients treated with the SSRI citalopram and patients treated with placebo. 2. Changes in rectosigmoid visceral sensitivity, assessed by barostat balloon distention, do not differ between patients treated with the SSRI citalopram and patients treated with placebo.

Irritable Bowel Syndrome

Stanford University54 participantsStarted Apr 2001

San Francisco, California, United States

COMPLETEDPhase 3< 1 mile

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468

An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.

Purpura, Thrombocytopaenic, Idiopathic

Novartis Pharmaceuticals302 participantsStarted Jun 2006

Huntsville, Alabama, United States • Mobile, Alabama, United States • Jonesboro, Arkansas, United States +107 more locations

Citalopram in Irritable Bowel Syndrome

EXTEND (Eltrombopag Extended Dosing Study)

Find Trials by Condition in San Francisco

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Thiazolidinedione Intervention With Vitamin D Evaluation

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Safety and Efficacy of Cariprazine for Bipolar I Disorder

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer